AIDX
20/20 Biolabs, Inc. · Services
20/20 Biolabs, Inc. (AIDX) has 4 SEC Form 4 filings (5 transaction rows) in the rolling window, disclosed by 0 distinct insiders. Most recent filing: Feb 23, 2026.
- Industry:Medical - Care Facilities
- CEO:Jonathan Cohen
- Employees:14
- HQ:Gaithersburg, MD, US
- IPO:2026-02-19
No open-market insider trades for AIDX (20/20 Biolabs, Inc.) in the last 365 days.
Why this page may be quiet. Tracefour displays Form 4 open-market purchases (P) and sales (S): the two transaction codes that signal directional conviction. Restricted stock grants, option exercises, gifts, and tax-withholding sales are filed but intentionally not shown: they're disclosure mechanics, not buy/sell decisions.
Many large-cap executives trade through pre-scheduled 10b5-1 plans set months in advance and batch-disclosed each quarter, so the latest filing on EDGAR for a mega-cap can be weeks old without any insider actually choosing to trade in that window.
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does AIDX have?
20/20 Biolabs, Inc. (AIDX) has 4 SEC Form 4 filings (5 transaction rows) in the rolling 365-day window, disclosed by 0 distinct insiders. Most recent filing: Feb 23, 2026.
When was the most recent SEC Form 4 filing for AIDX?
The most recent Form 4 filing for AIDX on Tracefour is dated Feb 23, 2026.
Can I get alerts for AIDX insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at 20/20 Biolabs, Inc. (AIDX). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
20/20 Biolabs, Inc. is in the Services sector.